3D Cell Culture Technologies Global Market Report 2024

The 3d cell culture technologies market size has grown rapidly in recent years. It will grow from $2.85 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 19.0%. The growth observed in the historical period can be attributed to progress in the field of cell biology, advancements in drug development, the increasing prevalence of chronic diseases, and government funding support.

The 3d cell culture technologies market size is expected to see rapid growth in the next few years. It will grow to $6.94 billion in 2028 at a compound annual growth rate (CAGR) of 19.6%. The anticipated growth in the forecast period can be attributed to factors such as the expanding pharmaceutical industry, a surge in research and development activities, as well as growing environmental and ethical considerations. Notable trends expected during this period encompass personalized medicine, continuous technological advancements, the emergence of bioprinting, and the advancement of regenerative medicine.

The demand for organ transplantation is a key driver for the 3D Cell Culture Technologies Market. 3D cell culture plays a crucial role in creating three-dimensional structures that closely resemble tissues and organs, making it instrumental for successful organ transplantation. Furthermore, 3D cell structures offer the potential for tissue and organ regeneration and serve as a valuable tool for drug toxicity screening. For instance, in January 2023, data from the United Network for Organ Sharing (UNOS), a US-based non-profit organization, revealed that in 2022, the United States witnessed a 3.7% increase in organ transplants, with 42,887 procedures performed. A record-breaking 14,903 individuals became deceased organ donors in 2022, marking the twelfth consecutive year of growth and a 7.5% increase over 2021. This growth is partly attributed to the broadening of medical criteria for deceased organ donation based on positive clinical outcomes, leading to a higher proportion of donors from non-traditional eligibility categories. Notably, there was a nearly 14% increase in donations after circulatory death (DCD donors) in 2022 compared to 2021, and for the first time, there were more than 5,000 donors aged 50 or older in a single year, with 5,789 in total.

The primary categories of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. 3D bioreactors, for instance, are specialized plastic cylinder chambers tailored for cultivating cells in a three-dimensional fashion. These technologies find application in various fields, including cancer research, stem cell research, drug discovery, and regenerative medicine. They are utilized by a wide range of users, including research laboratories, biotechnology and pharmaceutical companies, hospitals, diagnostic centers, and other institutions.

The 3D cell culture technologies market research report is one of a series of new reports that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticipated growth of the 3D cell culture technologies market is largely attributed to the increasing momentum in drug discovery. Drug discovery involves the exploration of potential new medicinal compounds through a combination of computational, experimental, translational, and clinical models. Notably, 3D cell culture technologies are gaining significance in the realm of drug discovery due to their ability to provide more precise and dependable results. They enable microscale 3D cultures, offer higher predictive value for clinical outcomes, and eliminate the need for animal models. For example, as of January 2023, the Food and Drug Administration (FDA), a US federal agency under the Department of Health and Human Services, reported the approval of 37 new drugs and therapeutic biological products by the FDA's Centre for Drug Evaluation and Research (CDER) in the United States for various medical indications in 2022. This reaffirms the crucial role of 3D cell culture technologies in advancing drug discovery, making it a driving force behind the growth of the 3D cell culture technologies market.

The 3D Cell Culture technologies market is facing constraints due to the potential risk of cell contamination. Cell culture contamination, in this context, pertains to the presence of bacteria, molds, yeasts, viruses, and mycoplasma, which can have detrimental effects on the cell culture process. Contamination typically occurs due to improper handling of cells or a lack of appropriate care, ultimately affecting the regeneration process. A study conducted by Yale and Tufts University underscores the greater complexity of 3D cultures compared to their 2D counterparts. To accurately mimic tissue or organ structures, 3D cell cultures demand a highly controlled cellular environment. Consequently, the probability of cell culture contamination is relatively higher in the case of 3D cell cultures, posing a challenge for this market.

The current trend in the 3D Cell Culture market revolves around the adoption of cutting-edge technology. Several companies have embraced a notable advancement in this sector, namely the utilization of in vivo/in vitro environments. Traditional cell expansion and interactions in 2D in vitro models have limitations, but when compared to the 3D cell culture technique, the latter offers a more conducive environment for cell culture. The in vitro environment empowers researchers and medical professionals to carry out procedures within a controlled setting outside the living organism. This approach is gaining significant importance, particularly in the context of patient health monitoring. Notably, the FDA has granted approval for Biotek's 3D cell expansion system to be used as a medical device. Additionally, Biotek's Polycaprolactone (PCL), a biodegradable polyester material utilized in numerous FDA-approved implants and drug delivery devices, has also received FDA approval. This reflects the growing significance of advanced technology adoption in the 3D Cell Culture market.

Prominent players in the 3D Cell Culture Technologies market are strategically introducing innovative products, such as PODS-PeptiGels, to enhance their competitive position. PODS-PeptiGels represents a novel approach that combines two advanced cell culture technologies such as synthetic peptide hydrogels (PeptiGels) and a diverse array of sustained-release growth factors (PODS). This combination results in a reproducible and highly adaptable environment for 3D cell culture. For example, in April 2022, as reported by Cell Guidance Systems, a UK-based biotechnology company, a collaboration with Manchester BIOGEL led to the launch of PODS-PeptiGels for 3D cell culture. This ready-to-use kit empowers researchers to customize their approach to align with the objectives of their research. They can choose from a selection of over 70 growth factors and combine them with a wide variety of hydrogels, each offering specific mechanical and biomimetic properties. Manchester Biogel, another UK-based biotechnology company, specializes in the design and manufacturing of 3D synthetic peptide hydrogels. This strategic introduction of innovative products demonstrates a commitment to staying competitive in the 3D Cell Culture Technologies market.

In May 2021, the USA-based start-up CELLINK Group, specializing in the design and provision of technologies and services to advance biological research, successfully completed the acquisition of Visikol Corporation for a sum of $7.5 million. This strategic acquisition marked CELLINK's foray into the contract research market. Visikol Corporation, an American contract research services firm, is known for offering top-tier services in areas such as 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology, catering primarily to the pharmaceutical and biotechnology sectors.

Major companies operating in the 3D cell culture technologies market include Becton Dickinson and Company, Corning Incorporated, Eppendorf AG, GE Healthcare a division of General Electric Company, Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, HiMedia Laboratories Pvt. Ltd., Agilent Technologies Inc., PromoCell GmbH, CellGenix GmbH, Greiner Bio-One International GmbH, Irvine Scientific Sales Company Inc., Cell Culture Company LLC, SeraCare Life Sciences Inc., American Type Culture Collection (ATCC), Miltenyi Biotec B.V. & Co. KG, AITbiotech Pte Ltd, Essen BioScience a Sartorius Company, Sigma-Aldrich, Bel-Art Products Inc., MilliporeSigma, Sumitomo Bakelite, EMD Millipore, Affymetrix Inc., VWR International llc., WHEATON IndustriesInc, Sartorius AG, CN Bio Innovations, Nortis Inc., Kiyatec, Nanofiber Solutions, Copner Biotech, Known Medicine, Synthecon Inc., 3D Biotek LLC, 3D Cell Culture Innovations LLC., 3D Matrix Inc., Allevi Inc., BioSpherix Ltd., Emulate Inc., MicroTissues Inc.

North America was the largest region in the 3D cell culture technologies market in 2023. Western Europe was the second largest region in the 3D cell culture technologies market. The regions covered in the 3d cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the 3d cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.